5-乙基-4-甲基噻唑 | 31883-01-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 5-乙基-4-甲基噻唑
• 中文别名: 5-乙基-4-甲基
• 英文名称: 4-methyl-5-ethylthiazole
• 英文别名: 5-ethyl-4-methylthiazole；5-ethyl-4-methyl-thiazole；5-Aethyl-4-methyl-thiazol；4-Methyl-5-ethyl-thiazol；5-Aethyl-4-methylthiazol；5-ethyl-4-methyl-1,3-thiazole
• CAS: 31883-01-9
• 化学式: C₆H₉NS
• 分子量: 127.21
• InChiKey: XPQULTFBJPGINB-UHFFFAOYSA-N

物化性质

• 沸点：
  181°C (estimate)
• 密度：
  1.042 (estimate)
• LogP：
  1.694 (est)
• 保留指数：
  988;991;989;1004;988;991;986;1023

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  41.1
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2934100090

反应信息

• 作为反应物：
  描述：

  5-乙基-4-甲基噻唑 、 1,12-二碘十二烷 以 乙腈 为溶剂， 反应 72.0h， 以70%的产率得到1,12-dodecanemethylenebis(4-methyl-5-ethylthiazolium) diiodide
  参考文献：
  名称：

  Mono- and Bis-Thiazolium Salts Have Potent Antimalarial Activity

  摘要：

  Three new series comprising 24 novel cationic choline analogues and consisting of mono- or his (N or C-5-duplicated) thiazolium salts have been synthesized. Bis-thiazolium salts showed potent antimalarial activity (much superior to monothiazoliums). Among them, bis-thiazolium salts 12 and 13 exhibited IC50 values of 2.25 nM and 0.65 nM, respectively, against P. falciparum in vitro. These compounds also demonstrated good in vivo activity (ED50 <= 0.22 mg/kg), and low toxicity in mice infected by Plasmodium vinckei.

  DOI：

  10.1021/jm0492608
• 作为产物：
  描述：

  2-氯-2-乙基-3-氧代丁酸乙酯 在 溶剂黄146 作用下， 生成 5-乙基-4-甲基噻唑
  参考文献：
  名称：

  Thiamin Analogs. II. 4-Methylthiazole Analogs^1,2

  摘要：

  DOI：

  10.1021/ja01219a012

文献信息

• [EN] THERAPEUTIC COMPOUNDS AND COMPOSITIONS<br/>[FR] COMPOSÉS ET COMPOSITIONS THÉRAPEUTIQUES
  申请人：AGIOS PHARMACEUTICALS INC

  公开号：WO2014139325A1

  公开（公告）日：2014-09-18

  Compounds of general formula (I) and compositions comprising compounds of general formula (I) that modulate pyruvate kinase are described herein. Also described herein are methods of using the compounds that modulate pyruvate kinase in the treatment of diseases.

  本文描述了一般式（I）化合物和包含调节丙酮酸激酶的一般式（I）化合物的组合物。本文还描述了利用调节丙酮酸激酶的这些化合物治疗疾病的方法。
• HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS
  申请人：CHANGZHOU YINSHENG PHARMACEUTICAL CO., LTD.

  公开号：US20170253614A1

  公开（公告）日：2017-09-07

  A series of hepatitis C virus (HCV) inhibitors and compositions and applications thereof in the preparation of drugs for treating chronic HCV infection. Especially, a series of compounds that are used as NS5A inhibitors, and compositions and uses thereof in the preparations of drugs.

  一系列丙型肝炎病毒（HCV）抑制剂及其组合物，以及在制备用于治疗慢性HCV感染的药物时的应用。特别是一系列用作NS5A抑制剂的化合物，以及在药物制剂中的组合物和用途。
• [EN] STAT DEGRADERS AND USES THEREOF<br/>[FR] AGENTS DE DÉGRADATION DE STAT ET LEURS UTILISATIONS
  申请人：KYMERA THERAPEUTICS INC

  公开号：WO2021188696A1

  公开（公告）日：2021-09-23

  The present invention provides compounds, compositions thereof, and methods of using the same.

  本发明提供了化合物、其组合物以及使用相同的方法。
• 1-Oxo-1H-thiazolo[3,2-a]pyrimidine-2-carboxamides
  申请人：Pfizer Inc.

  公开号：US04414388A1

  公开（公告）日：1983-11-08

  Antiallergy and antiulcer agents having the formula (I), ##STR1## and their pharmaceutically acceptable salts, wherein R.sub.1 and R.sub.2 taken separately are each hydrogen or lower alkyl; and R.sub.1 and R.sub.2 taken together are alkylene of 3-9 carbon atoms or phenylalkylene of 9-11 carbon atoms, with the proviso that the ring so formed is between 5- and 8-membered; acids of the formula (II), ##STR2## wherein R.sub.1 and R.sub.2 are as defined above and R.sub.3 is hydrogen, which are useful as intermediates for compounds of the formula (I), but in many instances also possess the same useful biological activity as do formula I compounds; and intermediates of the formula II wherein R.sub.1 and R.sub.2 are defined as above, and R.sub.3 is alkyl of 1 to 4 carbon atoms, carbalkoxy of 2 to 5 carbon atoms, carbophenoxy or carbobenzoxy, are also described.

  抗过敏和抗溃疡药物具有以下式(I)的结构，及其药学上可接受的盐，其中R.sub.1和R.sub.2分别为氢或较低的烷基；R.sub.1和R.sub.2一起为3-9个碳原子的烷基或9-11个碳原子的苯基烷基，但所形成的环在5-至8-成员之间；式(II)的酸，其中R.sub.1和R.sub.2如上定义，R.sub.3为氢，这些酸是化合物(I)的中间体，但在许多情况下也具有与化合物I相同的有用生物活性；以及式(II)的中间体，其中R.sub.1和R.sub.2如上定义，R.sub.3为1至4个碳原子的烷基，2至5个碳原子的羰基烷基，羰基苯氧基或羰基苯甲氧基。
• ANTI-ENTEROVIRUS 71 THIADIAZOLIDINE DERIVATIVE
  申请人：JIANGSU KANION PHARMACEUTICAL CO. LTD

  公开号：US20170066732A1

  公开（公告）日：2017-03-09

  Disclosed is a novel anti-enterovirus 71 (EV71) 1,2,5-thiadiazolidine-1,1-dioxide derivative or a pharmaceutically acceptable salt thereof; and specifically, a compound represented by formula (II) or a pharmaceutically acceptable salt thereof.

  揭示了一种新型抗肠道病毒71（EV71）1,2,5-噻二唑啉-1,1-二氧化物衍生物或其药用盐；具体而言，是由式（II）表示的化合物或其药用盐。

表征谱图